All In Biotech

NDA 204017 · Agile

Twirla

Ethinyl Estradiol, Levonorgestrel · Transdermal · Progestin; Progestin-containing Intrauterine System; Estrogen

Last checked: Nov 19, 2026Latest source record: Jun 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Feb 14, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

501

113 Phase 3, 20 recruiting

FAERS reports

1,083

36 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS and CONTRAINDICATED IN WOMEN WITH A BMI ≥ 30 KG/M 2 Cigarette Smoking and Serious Cardiovascular Events Cigarette smoking increases the risk of serious cardiovascular events from combined hormonal contraceptive (CHC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, CHCs, including TWIRLA, are contraindicated in women who are over 35 years of age and smoke [see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 )]. Contraindicated in Women with a BMI ≥ 30 kg/m 2 TWIRLA is contraindicated in women with a BMI ≥ 30 kg/m 2 . Compared to women with a lower BMI, women with a BMI ≥ 30 kg/m 2 had reduced effectiveness and may have a higher risk for venous thromboembolism events (VTEs) [see Contraindications ( 4 ) and Warnings and...

What it is approved for

From the label in effect Jun 30, 2026.

TWIRLA is indicated as a method of contraception for use in women of reproductive potential with a BMI < 30 kg/m 2 for whom a combined hormonal contraceptive is appropriate. Limitation of Use Consider TWIRLA’s reduced effectiveness in women with a BMI ≥ 25 to < 30 kg/m 2 before prescribing TWIRLA [see Use in Specific Populations ( 8.9 ) and Clinical Studies ( 14 )] . TWIRLA is contraindicated in women with a BMI ≥ 30 kg/m 2 [see Contraindications ( 4 )] . TWIRLA is a combination of levonorgestrel, a progestin, and ethinyl estradiol, an estrogen, indicated as a method of contraception for use in women of reproductive potential with a BMI < 30 kg/m 2 for whom a combined hormonal contraceptive is appropriate. ( 1 ) Limitation of Use Consider TWIRLA’s reduced effectiveness in women with a BMI ≥ 25 to < 30 kg/m 2 before prescribing. ( 4 , 8.9 , 14 )

Mechanism: Combination hormonal contraceptives lower the risk of becoming pregnant primarily by suppressing ovulation.

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • TWIRLA · ETHINYL ESTRADIOL 0.01MG/24HR; LEVONORGESTREL 0.04MG/24HR · SYSTEM, TRANSDERMAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ethinyl Estradiol" as an intervention, any sponsor and status, largest first.

All 501 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product adhesion issue553
  • intermenstrual bleeding134
  • menstrual disorder95
  • product administration error49
  • application site rash38
  • wrong technique in product usage process31
  • application site pruritus28
  • product dose omission issue28
  • heavy menstrual bleeding27
  • off label use25
  • application site irritation24
  • incorrect product administration duration23

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20121
20141
20163
20173
20192
20201
2021115
2022304
202389
2024233
2025222
2026109

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,068 on PubMed

Sponsor: Agile

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.